The cup runneth over: Lessons from the ever-expanding pool of primary immunodeficiency diseases

Nature Reviews Immunology

Volumn 13, Issue 9, 2013, Pages 635-648

  Milner, Joshua D ^a   Holland, Steven M ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD150 ANTIGEN; FOCAL ADHESION KINASE 1; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 21; INTERLEUKIN 21 RECEPTOR; INTERLEUKIN 22; INTERLEUKIN 7 RECEPTOR ALPHA; KHELLIN; STAT3 PROTEIN; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR GATA 2;

AUTOIMMUNITY; AUTOSOMAL DOMINANT DISORDER; B LYMPHOCYTE ACTIVATION; BONE MARROW TRANSPLANTATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL DIVISION; CELL MATURATION; CELL PROLIFERATION; COLD URTICARIA; CYTOKINESIS; DENDRITIC CELL; ENZYME ACTIVITY; GAIN OF FUNCTION MUTATION; GENE MUTATION; GLUCOSE HOMEOSTASIS; HOST RESISTANCE; HUMAN; HUMORAL IMMUNITY; HYPER IGE SYNDROME; IMMUNE DEFICIENCY; IMMUNE DYSREGULATION; IMMUNE RESPONSE; IMMUNOLOGICAL SYNAPSE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; INHERITANCE; LOSS OF FUNCTION MUTATION; LYMPHOCYTOPENIA; MEMORY T LYMPHOCYTE; MUCOCUTANEOUS CANDIDIASIS; NATURAL KILLER CELL; NONHUMAN; OMENN SYNDROME; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; PRE B LYMPHOCYTE; PRIORITY JOURNAL; RESPIRATORY CHAIN; RESPIRATORY TRACT INFECTION; REVIEW; SECOND MESSENGER; SEVERE COMBINED IMMUNODEFICIENCY; SIGNAL TRANSDUCTION; UPREGULATION; WISKOTT ALDRICH SYNDROME;

ANIMALS; B-LYMPHOCYTES; CYTOKINES; HUMANS; IMMUNITY, HUMORAL; IMMUNITY, INNATE; IMMUNOLOGIC DEFICIENCY SYNDROMES; MUTATION;

EID: 84883162002     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri3493     Document Type: Review

References (122)

1. Ochs, H. D. & Hitzig, W. H. History of primary immunodeficiency diseases. Curr. Opin. Allergy Clin. Immunol. 12, 577-587 (2012).
2. Bruton, O. C. Agammaglobulinemia. Pediatrics 9, 722-728 (1952).
3. Casanova, J. L. & Abel, L. Primary immunodeficiencies: a field in its infancy. Science 317, 617-619 (2007).
4. Davis, M. M. Immunology taught by humans. Sci. Transl. Med. 4, 117fs112 (2012).
5. Zhang, Q. et al. Combined immunodeficiency associated with DOCK8 mutations. N. Engl. J. Med. 361, 2046-2055 (2009).
6. Sanal, O. et al. Additional diverse findings expand the clinical presentation of DOCK8 deficiency. J. Clin. Immunol. 32, 698-708 (2012).
7. Jabara, H. H. et al. DOCK8 functions as an adaptor that links TLR-MyD88 signaling to B cell activation. Nature Immunol. 13, 612-620 (2012).
8. Picard, C. et al. Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency. Medicine 89, 403-425 (2010).
9. Weller, S. et al. IgM+IgD+CD27+ B cells are markedly reduced in IRAK-4-, MyD88-, and TIRAP-but not UNC-93B-deficient patients. Blood 120, 4992-5001 (2012).
10. He, B. et al. The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88. Nature Immunol. 11, 836-845 (2010).
11. Isnardi, I. et al. IRAK-4-and MyD88-dependent pathways are essential for the removal of developing autoreactive B cells in humans. Immunity 29, 746-757 (2008).
12. Randall, K. L. et al. DOCK8 deficiency impairs CD8 T cell survival and function in humans and mice. J. Exp. Med. 208, 2305-2320 (2011).
13. Randall, K. L., Lambe, T., Goodnow, C. C. & Cornall, R. J. The essential role of DOCK8 in humoral immunity. Dis. Markers 29, 141-150 (2010).
14. Mizesko, M. C. et al. Defective actin accumulation impairs human natural killer cell function in patients with dedicator of cytokinesis 8 deficiency. J. Allergy Clin. Immunol. 131, 840-848 (2013).
15. Harada, Y. et al. DOCK8 is a Cdc42 activator critical for interstitial dendritic cell migration during immune responses. Blood 119, 4451-4461 (2012).
16. Mueller, P. et al. Regulation of T cell survival through coronin-1-mediated generation of inositol-1,4,5-trisphosphate and calcium mobilization after T cell receptor triggering. Nature Immunol. 9, 424-431 (2008).
17. Shiow, L. R. et al. The actin regulator coronin 1A is mutant in a thymic egress-deficient mouse strain and in a patient with severe combined immunodeficiency. Nature Immunol. 9, 1307-1315 (2008).
18. Moshous, D. et al. Whole-exome sequencing identifies coronin-1A deficiency in 3 siblings with immunodeficiency and EBV-associated B-cell lymphoproliferation. J. Allergy Clin. Immunol. 131, 1594-1603.e9 (2013).
19. Pan, D. The hippo signaling pathway in development and cancer. Dev. Cell 19, 491-505 (2010).
20. Nehme, N. T. et al. MST1 mutations in autosomal recessive primary immunodeficiency characterized by defective naive T-cell survival. Blood 119, 3458-3468 (2012).
21. Abdollahpour, H. et al. The phenotype of human STK4 deficiency. Blood 119, 3450-3457 (2012).
22. Crequer, A. et al. Inherited MST1 deficiency underlies susceptibility to EV-HPV infections. PLoS ONE 7, e44010 (2012).
23. Heallen, T. et al. Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. Science 332, 458-461 (2011).
24. Mou, F. et al. The Mst1 and Mst2 kinases control activation of rho family GTPases and thymic egress of mature thymocytes. J. Exp. Med. 209, 741-759 (2012).
25. Palendira, U. et al. Molecular pathogenesis of EBV susceptibility in XLP as revealed by analysis of female carriers with heterozygous expression of SAP. PLoS Biol. 9, e1001187 (2011).
26. Palendira, U. et al. Expansion of somatically reverted memory CD8+ T cells in patients with X-linked lymphoproliferative disease caused by selective pressure from Epstein-Barr virus. J. Exp. Med. 209, 913-924 (2012).
27. Li, F. Y. et al. Second messenger role for Mg2+ revealed by human T-cell immunodeficiency. Nature 475, 471-476 (2011).
28. Niehues, T., Perez-Becker, R. & Schuetz, C. More than just SCID-the phenotypic range of combined immunodeficiencies associated with mutations in the recombinase activating genes (RAG) 1 and 2. Clin. Immunol. 135, 183-192 (2010).
29. Omenn, G. S. Familial reticuloendotheliosis with eosinophilia. N. Engl. J. Med. 273, 427-432 (1965).
30. Schuetz, C. et al. An immunodeficiency disease with RAG mutations and granulomas. N. Engl. J. Med. 358, 2030-2038 (2008).
31. De Ravin, S. S. et al. Hypomorphic Rag mutations can cause destructive midline granulomatous disease. Blood 116, 1263-1271 (2010).
32. Avila, E. M. et al. Highly variable clinical phenotypes of hypomorphic RAG1 mutations. Pediatrics 126, e1248-e1252 (2010).
33. Kuijpers, T. W. et al. Idiopathic CD4+ T lymphopenia without autoimmunity or granulomatous disease in the slipstream of RAG mutations. Blood 117, 5892-5896 (2011).
34. de Villartay, J. P. et al. A novel immunodeficiency associated with hypomorphic RAG1 mutations and CMV infection. J. Clin. Invest. 115, 3291-3299 (2005).
35. Marrella, V. et al. A hypomorphic R229Q Rag2 mouse mutant recapitulates human Omenn syndrome. J. Clin. Invest. 117, 1260-1269 (2007).
36. Walter, J. E. et al. Expansion of immunoglobulin-secreting cells and defects in B cell tolerance in Rag-dependent immunodeficiency. J. Exp. Med. 207, 1541-1554 (2010).
37. Cassani, B. et al. Homeostatic expansion of autoreactive immunoglobulin-secreting cells in the Rag2 mouse model of Omenn syndrome. J. Exp. Med. 207, 1525-1540 (2010).
38. Milner, J. D., Ward, J. M., Keane-Myers, A. & Paul, W. E. Lymphopenic mice reconstituted with limited repertoire T cells develop severe, multiorgan, Th2-associated inflammatory disease. Proc. Natl Acad. Sci. USA 104, 576-581 (2007).
39. Rucci, F. et al. Abnormalities of thymic stroma may contribute to immune dysregulation in murine models of leaky severe combined immunodeficiency. Front. Immunol. http://dx.doi.org/10.3389/fimmu.2011.00015 (2013).
40. Conley, M. E. et al. Agammaglobulinemia and absent B lineage cells in a patient lacking the p85? subunit of PI3K. J. Exp. Med. 209, 463-470 (2012).
41. Fruman, D. A. et al. Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85?. Nature Genet. 26, 379-382 (2000).
42. Datta, S. & Milner, J. D. Altered T-cell receptor signaling in the pathogenesis of allergic disease. J. Allergy Clin. Immunol. 127, 351-354 (2011).
43. Gandhi, C., Healy, C., Wanderer, A. A. & Hoffman, H. M. Familial atypical cold urticaria: description of a new hereditary disease. J. Allergy Clin. Immunol. 124, 1245-1250 (2009).
44. Ombrello, M. J. et al. Cold urticaria, immunodeficiency, and autoimmunity related to PLCG2 deletions. N. Engl. J. Med. 366, 330-338 (2012).
45. Wang, D. et al. Phospholipase C?2 is essential in the functions of B cell and several Fc receptors. Immunity 13, 25-35 (2000).
46. Yu, P. et al. Autoimmunity and inflammation due to a gain-of-function mutation in phospholipase C?2 that specifically increases external Ca2+ entry. Immunity 22, 451-465 (2005).
47. Abe, K. et al. A novel N-ethyl-N-nitrosourea-induced mutation in phospholipase C2 causes inflammatory arthritis, metabolic defects, and male infertility in vitro in a murine model. Arthritis Rheum. 63, 1301-1311 (2011).
48. Freeman, A. F. et al. Coronary artery abnormalities in Hyper-IgE syndrome. J. Clin. Immunol. 31, 338-345 (2011).
49. Fairchild, K. D., Singh, I. S., Carter, H. C., Hester, L. & Hasday, J. D. Hypothermia enhances phosphorylation of IB kinase and prolongs nuclear localization of NF-B in lipopolysaccharide-activated macrophages. Am. J. Physiol. Cell Physiol. 289, C1114-C1121 (2005).
50. Zhou, Q. et al. A hypermorphic missense mutation in PLCG2, encoding phospholipase C2, causes a dominantly inherited autoinflammatory disease with immunodeficiency. Am. J. Hum. Genet. 91, 713-720 (2012). References 44 and 50 show the remarkable complexity and the diversity of cellular and clinical phenotypes, including allergy, immunodeficiency and autoinflammation, which emerge from two different types of gain-of-function mutations in PLCG2.
51. Casanova, J. L., Abel, L. & Quintana-Murci, L. Human TLRs and IL-1Rs in host defense: natural insights from evolutionary, epidemiological, and clinical genetics. Annu. Rev. Immunol. 29, 447-491 (2011).
52. Sancho-Shimizu, V. et al. Herpes simplex encephalitis in children with autosomal recessive and dominant TRIF deficiency. J. Clin. Invest. 121, 4889-4902 (2011).
53. Guo, Y. et al. Herpes simplex virus encephalitis in a patient with complete TLR3 deficiency: TLR3 is otherwise redundant in protective immunity. J. Exp. Med. 208, 2083-2098 (2011).
54. Perez de Diego, R. et al. Human TRAF3 adaptor molecule deficiency leads to impaired Toll-like receptor 3 response and susceptibility to herpes simplex encephalitis. Immunity 33, 400-411 (2010).
55. Zhang, S. Y. et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science 317, 1522-1527 (2007).
56. Casrouge, A. et al. Herpes simplex virus encephalitis in human UNC-93B deficiency. Science 314, 308-312 (2006).
57. Herman, M. et al. Heterozygous TBK1 mutations impair TLR3 immunity and underlie herpes simplex encephalitis of childhood. J. Exp. Med. 209, 1567-1582 (2012).
58. Lafaille, F. G. et al. Impaired intrinsic immunity to HSV-1 in human iPSC-derived TLR3-deficient CNS cells. Nature 491, 769-773 (2012).
59. Vinh, D. C. et al. Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. Blood 115, 1519-1529 (2010).
60. Hsu, A. P. et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood 118, 2653-2655 (2011).
61. Bigley, V. et al. The human syndrome of dendritic cell, monocyte, B and NK lymphoid deficiency. J. Exp. Med. 208, 227-234 (2011).
62. Ostergaard, P. et al. Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Nature Genet. 43, 929-931 (2011).
63. Hahn, C. N. et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nature Genet. 43, 1012-1017 (2011). References 60, 62 and 63 provide examples of multiple discrete phenotypes that arise from mutations in a single gene.
64. Rodrigues, N. P. et al. Haploinsufficiency of GATA-2 perturbs adult hematopoietic stem-cell homeostasis. Blood 106, 477-484 (2005).
65. Kumar, M. S. et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 149, 642-655 (2012).
66. Vicente, C. et al. Overexpression of GATA2 predicts an adverse prognosis for patients with acute myeloid leukemia and it is associated with distinct molecular abnormalities. Leukemia 26, 550-554 (2012).
67. Zhang, S. J. et al. Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia. Proc. Natl Acad. Sci. USA 105, 2076-2081 (2008).
68. Johnson, K. D. et al. Cis-element mutated in GATA2-dependent immunodeficiency governs hematopoiesis and vascular integrity. J. Clin. Invest. 122, 3692-3704 (2012).
69. Mace, E. M. et al. Mutations in GATA2 cause human NK cell deficiency with specific loss of the CD56bright subset. Blood 121, 2669-2677 (2013).
70. Biron, C. A., Byron, K. S. & Sullivan, J. L. Severe herpesvirus infections in an adolescent without natural killer cells. N. Engl. J. Med. 320, 1731-1735 (1989).
71. Kazenwadel, J. et al. Loss-of-function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature. Blood 119, 1283-1291 (2012).
72. Cuellar-Rodriguez, J. et al. Successful allogeneic hematopoietic stem cell transplantation for GATA2 deficiency. Blood 118, 3715-3720 (2011).
73. Marquis, J. F. et al. Interferon regulatory factor 8 regulates pathways for antigen presentation in myeloid cells and during tuberculosis. PLoS Genet. 7, e1002097 (2011).
74. Holtschke, T. et al. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 87, 307-317 (1996).
75. Hambleton, S. et al. IRF8 mutations and human dendritic-cell immunodeficiency. N. Engl. J. Med. 365, 127-138 (2011).
76. Chen, Z. & O'Shea, J. J. Th17 cells: a new fate for differentiating helper T cells. Immunol. Res. 41, 87-102 (2008).
77. Milner, J. D. et al. Impaired TH17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 452, 773-776 (2008).
78. Ma, C. S. et al. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J. Exp. Med. 205, 1551-1557 (2008).
79. de Beaucoudrey, L. et al. Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J. Exp. Med. 205, 1543-1550 (2008).
80. Renner, E. D. et al. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced TH17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. J. Allergy Clin. Immunol. 122, 181-187 (2008).
81. Puel, A. et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 332, 65-68 (2011).
82. Kisand, K. et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J. Exp. Med. 207, 299-308 (2010).
83. Puel, A. et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J. Exp. Med. 207, 291-297 (2010). References 81-83 were the first to highlight the remarkably limited infectious phenotype (that is, increased susceptibility to chronic mucocutaneous candidiasis) that occurs in patients with focal defects in IL-17-mediated signalling. By contrast, IL-17 has been shown to protect against a wider range of infections in mice.
84. Ferwerda, B. et al. Human dectin-1 deficiency and mucocutaneous fungal infections. N. Engl. J. Med. 361, 1760-1767 (2009).
85. Glocker, E. O. et al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. N. Engl. J. Med. 361, 1727-1735 (2009).
86. Minegishi, Y. et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 448, 1058-1062 (2007).
87. Holland, S. M. et al. STAT3 Mutations in the Hyper-IgE Syndrome. N. Engl. J. Med. 357, 1608-1619 (2007).
88. Speckmann, C. et al. Reduced memory B cells in patients with hyper IgE syndrome. Clin. Immunol. 129, 448-454 (2008).
89. Avery, D. T. et al. B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J. Exp. Med. 207, 155-171 (2010).
90. Schmitt, N. et al. Human dendritic cells induce the differentiation of interleukin-21-producing T follicular helper-like cells through interleukin-12. Immunity 31, 158-169 (2009).
91. Ma, C. S. et al. Functional STAT3 deficiency compromises the generation of human T follicular helper cells. Blood 119, 3997-4008 (2012).
92. Cui, W., Liu, Y., Weinstein, J. S., Craft, J. & Kaech, S. M. An interleukin-21-interleukin-10-STAT3 pathway is critical for functional maturation of memory CD8+ T cells. Immunity 35, 792-805 (2011).
93. Siegel, A. M. et al. A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory. Immunity 35, 806-818 (2011).
94. Kida, H. et al. GP130-STAT3 regulates epithelial cell migration and is required for repair of the bronchiolar epithelium. Am. J. Pathol. 172, 1542-1554 (2008).
95. Kovacic, J. C. et al. Stat3-dependent acute Rantes production in vascular smooth muscle cells modulates inflammation following arterial injury in mice. J. Clin. Invest. 120, 303-314 (2010).
96. Chandesris, M. O. et al. Frequent and widespread vascular abnormalities in human signal transducer and activator of transcription 3 deficiency. Circ. Cardiovasc. Genet. 5, 25-34 (2012).
97. Nieminen, P. et al. Inactivation of IL11 signaling causes craniosynostosis, delayed tooth eruption, and supernumerary teeth. Am. J. Hum. Genet. 89, 67-81 (2011).
98. Wegrzyn, J. et al. Function of mitochondrial Stat3 in cellular respiration. Science 323, 793-797 (2009).
99. Gough, D. J. et al. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 324, 1713-1716 (2009).
100. van der Windt, G. J. et al. Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity 36, 68-78 (2012).
101. Liu, L. et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J. Exp. Med. 208, 1635-1648 (2011).
102. van de Veerdonk, F. L. et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N. Engl. J. Med. 365, 54-61 (2011).
103. Boisson-Dupuis, S. et al. Inborn errors of human STAT1: allelic heterogeneity governs the diversity of immunological and infectious phenotypes. Curr. Opin. Immunol. 24, 364-378 (2012).
104. Smeekens, S. P. et al. STAT1 hyperphosphorylation and defective IL12R/IL23R signaling underlie defective immunity in autosomal dominant chronic mucocutaneous candidiasis. PLoS ONE 6, e29248 (2011).
105. Sampaio, E. P. et al. Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis. J. Allergy Clin. Immunol. 131, 1624-1634 (2013).
106. Uzel, G. et al. Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathy-enteropathy-X-linked-like syndrome. J. Allergy Clin. Immunol. 131, 1611-1623. e3 (2013).
107. Romberg, N. et al. Gain-of-function STAT1 mutations are associated with PD-L1 overexpression and a defect in B-cell survival. J. Allergy Clin. Immunol. 131, 1691-1693 (2013).
108. Yang, X. P. et al. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nature Immunol. 12, 247-254 (2011).
109. Yoshimura, A., Nishinakamura, H., Matsumura, Y. & Hanada, T. Negative regulation of cytokine signaling and immune responses by SOCS proteins. Arthritis Res. Ther. 7, 100-110 (2005).
110. Grimbacher, B. et al. Hyper-IgE syndrome with recurrent infections-an autosomal dominant multisystem disorder. N. Engl. J. Med. 340, 692-702 (1999).
111. Rezaei, N., Notarangelo, L. & Aghamohammadi, A. Primary Immunodeficiency Diseases: Definition, Diagnosis, and Management 59-64 (Springer, 2008).
112. Lean, I. S., McDonald, V. & Pollok, R. C. The role of cytokines in the pathogenesis of Cryptosporidium infection. Curr. Opin. Infect. Dis. 15, 229-234 (2002).
113. Kotlarz, D. et al. Loss-of-function mutations in the IL-21 receptor gene cause a primary immunodeficiency syndrome. J. Exp. Med. 210, 433-443 (2013).
114. Recher, M. et al. IL-21 is the primary common ? chain-binding cytokine required for human B-cell differentiation in vivo. Blood 118, 6824-6835 (2011).
115. de Totero, D. et al. Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells. Blood 107, 3708-3715 (2006).
116. Kuhn, R., Lohler, J., Rennick, D., Rajewsky, K. & Muller, W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75, 263-274 (1993).
117. Glocker, E. O. et al. Infant colitis-it's in the genes. Lancet 376, 1272 (2010).
118. Glocker, E. O. et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N. Engl. J. Med. 361, 2033-2045 (2009).
119. Engelhardt, K. R. et al. Clinical outcome in IL-10-and IL-10 receptor-deficient patients with or without hematopoietic stem cell transplantation. J. Allergy Clin. Immunol. 131, 825-830 (2012).
120. Pickert, G. et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J. Exp. Med. 206, 1465-1472 (2009).
121. Sayos, J. et al.The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature 395, 462-469 (1998).
122. Chaigne-Delalande, B. et al. Mg2+ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D. Science 341, 186-191 (2013)